AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.
AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...
Honestly still reeling from part one of The Real Housewives of New York reunion—specifically thanks to the second-hand awkwardness that radiated from my screen when Andy Cohen asked Jessel Taank what ...